Femasys secures UK MHRA approval for FemBloc permanent birth control

FEMASYS INC

MHRA approval validates safety, quality, and effectiveness for UK market.
Follows CE mark for Europe; expands global commercialization strategy.
FemBloc is a non-surgical polymer that forms scar tissue for permanent occlusion.
UK's NHS offers pathway to broad adoption for innovative women's health solutions.
Company plans to secure a strategic partner for UK commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.